Accueil
Détail de l'éditeur
Documents disponibles chez cet éditeur (361)
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Rapport
This publication presents the data and findings of the risk assessment on MT-45 (1-cyclohexyl-4-(1, 2-diphenylethyl)piperazine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014. The main part of the publicatio[...]Rapport
OEDT = EMCDDA ; F. FAGGIANO ; R. MOLINAR | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2014During adolescence, some young people may experiment with both licit and illicit substances (alcohol, tobacco, cannabis and other drugs). This can have an impact on their behaviour, their relationships with others and how they function in societ[...]Rapport
FRANÇAIS : Cette « Question particulière » de l'OEDT concernant la recherche nationale en matière de drogue en Europe décrit brièvement le cadre dans lequel la recherche en matière de drogue est menée dans les pays européens. Elle examine plus[...]Rapport
OEDT = EMCDDA ; V. AUWÄRTER ; J. DE MORAIS ; A. GALLEGOS ; M. EVANS-BROWN ; R. CHRISTIE ; R. JORGE ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2021This report provides a technical review of the current body of knowledge regarding new benzodiazepines that are monitored by the EU Early Warning System. The aims of this report are to strengthen situational awareness of new benzodiazepines in E[...]Rapport
As more jurisdictions contemplate and pass laws to legalise cannabis for medical and non-medical purposes, the discussions about cannabis policy will likely become more intense in the EU. Member States can learn from these experiences and decide[...]Rapport
This paper gives an overview of some recent developments in the tools most commonly used to manage national drug policies: strategies, coordination mechanisms and evaluations. It is based on an analysis of reports on national drug policies compi[...]Rapport
The prescription of substitution drugs, such as methadone and buprenorphine, has become a mainstream, first-line treatment for opioid dependence, with around 700 000 of Europe's 1.3 million problem opioid users receiving substitution treatment t[...]Rapport
This update from the EU Early Warning System overviews the NPS situation in Europe in 2020-2021 and highlights emerging threats to support early warning, preparedness planning and response measures. In addition, it reflects on the changes and th[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. CHRISTIE ; R. JORGE ; J. DE MORAIS ; A. ALMEIDA ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2020In this update from the the EU Early Warning System aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency's early warning and risk-assessment activities. The report covers the p[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; W. FRANCIS ; R. CHRISTIE ; A. CUNNINGHAM ; J. SEKULA ; A. ALMEIDA ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2015FRANÇAIS : De nouvelles substances psychoactives (NSP ou «nouvelles drogues») ont été détectées dans l'Union européenne l'année dernière au rythme de deux par semaine environ. Au total, 101 nouvelles substances ont été signalées au système d'al[...]Rapport
This short report provides an overview of how European countries are developing innovative legal responses to the challenges presented to public health and drug policy by the rapidly evolving market for new psychoactive substances.Rapport
The European new psychoactive substances (NPS) market has increased at a speed that established drug control laws struggle to match. Various countries have therefore introduced new legal responses to this phenomenon, based either on existing law[...]Rapport
OEDT = EMCDDA ; L. VANDAM ; P. BORLE ; L. MONTANARI ; T. SURMONT ; A. PIRONA ; D. HEDRICH ; A. GALLEGOS ; N. SINGLETON ; J. MOUNTENEY ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Rapid communication | 2018This report looks at the use of new psychoactive substances (NPS) in prison settings. This is a rapidly developing phenomenon, but empirical data are currently scarce and patchy. There is growing evidence that NPS are responsible for a large sha[...]Rapport
P. GRIFFITHS ; L. VINGOE ; K. JANSEN ; J. SHERVAL ; R. LEWIS ; R. HARTNOLL ; M. NILSON | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 1997FRANÇAIS : Ce rapport rend compte des résultats de deux études, commissionnées par l'OEDT, menées par le National Addiction Centre (Londres) et le Centre for HIV/AIDS and Drug Studies (Edinbourg). Le terme de drogues synthétiques fait référenc[...]Rapport
G. BURKHART, Auteur ; J. FOUNTAIN, Éditeur scientifique | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2013Some commentators argue that programmes developed in North America (Canada and the US) are unlikely to work in European countries, due to differing cultural contexts and because most of the evidence for their effectiveness comes from North Ameri[...]